Skip to content 
Semaglutide is a GLP-1 receptor agonist. It is a peptide similar to the hormone GLP-1 and is used extensively in metabolic research for its potential effects on glucose metabolism.
Required to reconstitute lyophilized peptides before use in research.
Key findings from published peer-reviewed research studies.
Disclaimer: This product is intended for research use only. Not for human consumption, therapeutic use, or diagnostic purposes.
| Chemical Name | Semaglutide |
| CAS Number | 910463-68-2 |
| Molecular Formula | C₁₈₇H₂₉₁N₄₅O₅₉ |
| Molecular Weight | 4,113.58 g/mol |
| Peptide Length | 31 amino acids |
| Mechanism | GLP-1 receptor agonist (94% homology to native GLP-1) |
| Half-life | ~7 days (enabling once-weekly dosing) |
| Appearance | White to off-white lyophilized powder |
| Purity | ≥99% (HPLC) |
| Endotoxin Level | <0.1 EU/mg |
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with 94% structural homology to native human GLP-1. Its fatty acid side chain enables albumin binding, extending its half-life to approximately 7 days.
Semaglutide has one of the most extensive clinical trial programs in metabolic research, including the SUSTAIN series (diabetes), STEP program (obesity), PIONEER trials (oral formulation), and SELECT trial (cardiovascular outcomes).
Semaglutide is a GLP-1-only receptor agonist, while tirzepatide is a dual GIP/GLP-1 agonist. Both have shown significant efficacy, with head-to-head data (SURPASS-2) suggesting potential advantages for tirzepatide in certain endpoints.
Peer-reviewed publications and reference materials.
Our products are strictly intended for laboratory research use only. Not for human or animal consumption. By purchasing, you confirm that you are a licensed researcher or purchasing for research purposes.
